[Form 4] Vivani Medical, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Form 4 filing reveals that Alexandra L. Popoff, Director at Vivani Medical (VANI), received a non-qualified stock option grant on June 24, 2025. Key details of the transaction:

• Granted 35,135 stock options to purchase common stock
• Exercise price set at $1.27 per share
• Options expire on June 23, 2035
• Vesting occurs on earlier of: - First anniversary of grant date - Next annual stockholder meeting

This grant was made as part of the company's Non-Employee Director Compensation Policy. The vesting is subject to continued service through the vesting date. The filing was submitted through an attorney-in-fact on June 26, 2025.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Popoff Alexandra L.

(Last) (First) (Middle)

C/O VIVANI MEDICAL, INC.

1350 S. LOOP ROAD

(Street)

ALAMEDA CA 94502

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Vivani Medical, Inc. [ VANI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/24/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Non-Qualified Stock Option (right to buy)	$1.27	06/24/2025		A		35,135		(1)(2)	06/23/2035	Common Stock	35,135(2)	$1.27(2)	35,135(2)	D

Explanation of Responses:

1. Annual grant awarded pursuant to the Issuer's Non-Employee Director Compensation Policy.

2. The option vests in total on the earlier of (i) the first anniversary of the grant or (ii) the next annual meeting of stockholders, subject to continued service through such date.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Adam Mendelsohn, Attorney-in-fact	06/26/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What stock options did Alexandra Popoff receive from VANI (Vivani Medical) on June 24, 2025?

Alexandra Popoff received 35,135 non-qualified stock options with an exercise price of $1.27 per share. These options were granted as part of the company's Non-Employee Director Compensation Policy and will expire on June 23, 2035.

What is the vesting schedule for VANI director Alexandra Popoff's June 2025 stock options?

The stock options will vest in full on either (i) the first anniversary of the grant date or (ii) the next annual meeting of stockholders, whichever comes first. This vesting is subject to Popoff's continued service through the vesting date.

Who is Alexandra Popoff and what is her role at VANI?

Alexandra Popoff serves as a Director on Vivani Medical's (VANI) Board of Directors. This is confirmed by the Form 4 filing which indicates her relationship to the issuer as 'Director' and shows she receives compensation under the Non-Employee Director Compensation Policy.

When will Alexandra Popoff's VANI stock options expire?

The non-qualified stock options granted to Alexandra Popoff will expire on June 23, 2035, which is 10 years from the grant date of June 24, 2025.

What was the exercise price of VANI's director stock options granted in June 2025?

The exercise price for the non-qualified stock options granted to Director Alexandra Popoff was $1.27 per share.